ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
Author(s): ,
Maria-Victoria Mateos
Affiliations:
Hematology,Hospital Clinico Universitario de Salamanca-IBSAL,Salamanca,Spain
,
Philippe Moreau
Affiliations:
Hematology Department,University of Nantes,Nantes,France
,
James R. Berenson
Affiliations:
Institute for Myeloma and Bone Cancer Research,West Hollywood,United States
,
Katja Weisel
Affiliations:
Universitatsklinikum Tubingen,Tubingen,Germany
,
Antonio Lazzaro
Affiliations:
Department of Clinical Oncology and Hematology, Division of Hematology and Bone Marrow Transplant Center,Hospital Gulielmo da Saliceto,Piacenza,Italy
,
Kevin Song
Affiliations:
Leukemia/Bone Marrow Transplant Program of British Columbia,Vancouver,Canada
,
Meletios A. Dimopoulos
Affiliations:
National and Kapodistrian University of Athens,Athens,Greece
,
Mei Huang
Affiliations:
Amgen Inc.,Thousand Oaks,United States
,
Anita Zahlten-Kumeli
Affiliations:
Amgen Inc.,Thousand Oaks,United States
A. Keith Stewart
Affiliations:
Division of Hematology/Oncology, Mayo Clinic,Scottsdale,United States
EHA Learning Center. Victoria Mateos M. Jun 16, 2018; 214544
Maria Victoria Mateos
Maria Victoria Mateos

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: S849

Type: Oral Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 16:30 - 16:45

Location: Room A1

Background
Twice-weekly carfilzomib (K) at 20/27 mg/m2 is approved for the treatment of RRMM. To develop a more convenient K regimen, once-weekly K plus dexamethasone (d) was assessed in the phase 1/2 CHAMPION-1 study, establishing a maximum tolerated dose of K 20/70 mg/m2 for RRMM pts.

Aims
To present results from the pre-planned interim analysis of the phase 3 study A.R.R.O.W. comparing Kd once-weekly at 20/70 mg/m2 (once-weekly group) vs twice-weekly at 20/27 mg/m2 (twice-weekly group).

Methods
Pts with 2–3 prior therapies and prior exposure to proteasome inhibitor and immunomodulatory agent were eligible. Pts were randomized 1:1 to receive either once- or twice-weekly K plus d. The once-weekly group received K (30-min IV) on days (D) 1, 8, and 15 of all cycles (20 mg/m2 on D1 [cycle 1]; 70 mg/m2 thereafter). The twice-weekly group received K (10-min IV) on D1, 2, 8, 9, 15, and 16 (20 mg/m2 on D1 and 2 during cycle 1 and 27 mg/m2 thereafter). All pts received d at 40 mg on D1, 8, 15 (all cycles), and 22 (cycle 1–9 only). Treatment was given in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), overall survival, safety, and pharmacokinetics.

Results
Baseline characteristics were generally balanced. Median PFS (once- vs twice-weekly) was 11.2 mo vs 7.6 mo (hazard ratio = 0.69; 1-sided P=0.0014). ORR (once- vs twice-weekly) was 62.9% vs 40.8% (P<0.0001); 7.1% vs 1.7% had a complete response or better. Grade ≥3 adverse events (AEs) occurred in 67.6% (once-weekly) and 61.7% (twice-weekly). Treatment-related grade 5 AEs occurred in 5 pts (2.1%) (once-weekly) and 2 pts (0.9%) (twice-weekly). The incidence of grade ≥3 hypertension and cardiac failure (once- vs twice-weekly) was 5.9% vs 5.5% and 2.9% vs 4.3%, respectively.

Conclusion
Once-weekly Kd at 20/70 mg/m2 significantly improved PFS and ORR vs twice-weekly Kd at 20/27 mg/m2. The incidence of AEs was comparable between groups. No new safety risks were found in the once-weekly group. Overall, once-weekly Kd showed favorable benefit-risk profile with a convenient dosing regimen vs twice-weekly Kd.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical Trial, Multiple Myeloma, Phase III, Proteasome inhibitor

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings